Hidradenitis Suppurativa - KOL Insight

The treatment landscape for hidradenitis suppurativa (HS) is rapidly evolving with significant advancements in therapeutic options. Insights from leading KOLs provide a comprehensive review of the current and future treatment landscape for HS, highlighting the pivotal role of AbbVie's Humira (adalimumab) as the primary first-line biologic treatment, the promise of Novartis' Cosentyx (secukinumab) for patients who do not respond to or cannot tolerate adalimumab, and the emerging potential of UCB's Bimzelx (bimekizumab). Explore the evolving HS treatment algorithms and the implications for clinical practice and drug development.

Key questions answered:

• What is the current role of TNF inhibitors, such as Abbvie's Humira (adalimumab) and Johnson & Johnson/Merck & Co.'s Remicade (infliximab), in the treatment of HS? What changes are anticipated in their usage?
• How effective are secondary treatment options like Novartis' Cosentyx (secukinumab) for patients who do not respond to or cannot tolerate adalimumab?
• What is the emerging potential of UCB's Bimzelx (bimekizumab) in the HS treatment landscape, and what do the Phase III trial data suggest?
• What are the key efficacy and safety profiles of the leading biologic treatments for HS?
• How are treatment paradigms expected to evolve with the introduction of new therapies?
• What insights do leading Key Opinion Leaders (KOLs) provide on the current and future management strategies for HS?
• What are the anticipated changes in the usage of existing and emerging treatments for HS?
• What are the strategic implications of these developments for clinical practice and drug development in HS management?

Key brands covered in this report:

Companies: